ICATIBANT ACETATE - Generic Drug Details

What are the generic sources for icatibant acetate and what is the scope of patent protection?

Icatibant acetate is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa, Alembic, Caplin, Cipla, Eugia Pharma, Fresenius Kabi Usa, Glenmark Pharms Ltd, Jiangsu Hansoh Pharm, Nang Kuang Pharm Co, Teva Pharms Usa, and Wilshire Pharms Inc, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for icatibant acetate. Ten suppliers are listed for this compound.

Summary for ICATIBANT ACETATE

US Patents:	0
Tradenames:	2
Applicants:	11
NDAs:	11
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	27
Patent Applications:	266
What excipients (inactive ingredients) are in ICATIBANT ACETATE?	ICATIBANT ACETATE excipients list
DailyMed Link:	ICATIBANT ACETATE at DailyMed

Pharmacology for ICATIBANT ACETATE

Drug Class	Bradykinin B2 Receptor Antagonist
Mechanism of Action	Bradykinin B2 Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ICATIBANT ACETATE

B06AC	Drugs used in hereditary angioedema
B06A	OTHER HEMATOLOGICAL AGENTS
B06	OTHER HEMATOLOGICAL AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for ICATIBANT ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRAZYR	Injection	icatibant acetate	10 mg/mL	022150	2	2015-08-25

US Patents and Regulatory Information for ICATIBANT ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jiangsu Hansoh Pharm	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	211021-001	Mar 9, 2020	AP	RX	No	No
Takeda Pharms Usa	FIRAZYR	icatibant acetate	INJECTABLE;SUBCUTANEOUS	022150-001	Aug 25, 2011	AP	RX	Yes	Yes
Nang Kuang Pharm Co	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	212081-001	Dec 16, 2020	AP	RX	No	No
Teva Pharms Usa	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	210118-001	Jul 15, 2019	AP	RX	No	No

Expired US Patents for ICATIBANT ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	FIRAZYR	icatibant acetate	INJECTABLE;SUBCUTANEOUS	022150-001	Aug 25, 2011

ICATIBANT ACETATE Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Icatibant Acetate?

Icatibant acetate, marketed as Firazyr, is a medication approved for treating acute attacks of hereditary angioedema (HAE). The drug’s market environment is shaped by growth in HAE prevalence, regulatory approvals, competitive landscape, and pricing policies.

Market Overview and Growth Drivers

• Prevalence of HAE: Estimated at approximately 1 in 50,000 people globally, with higher rates in specific populations (1).
• Regulatory Approvals: Approved in over 50 countries, including the US (2011), EU (2012), and Japan (2018). Expansion into emerging markets continues.
• Clinical Adoption: Growing awareness and diagnosis rates have driven increased prescriptions, especially in developed markets with robust healthcare systems.
• Competitive Landscape: Icatibant faces competition primarily from plasma-derived C1-INH products (e.g., Berinert, Haegarda) and newer therapeutic classes like bradykinin B2 receptor antagonists under development.

Market Challenges

• Pricing and Reimbursement: High cost limits access; reimbursement policies vary. US list prices are around $2,000 per dose, with actual payer costs often lower due to negotiated discounts (2).
• Limited Indication Expansion: Current approval covers only acute HAE attacks; lack of prophylactic indication constrains market size.
• Manufacturing Constraints: Production complexities in peptide synthesis can impact supply stability and pricing.

Market Segmentation and Growth Prospects

• Geographic Markets: US and EU account for approximately 70% of revenues; Asia-Pacific, Middle East, and Latin America are emerging markets.
• Patient Pool Expansion: Increased diagnosis, genetic testing, and physician awareness are expected to grow the treated population by roughly 5–7% annually.
• Pipeline Developments: Several pipeline candidates aim at prophylaxis and different HAE subtypes; success could broaden the market, impacting revenue streams.

What Is the Financial Trajectory of Icatibant Acetate?

Financial forecasts for icatibant acetate depend on revenue growth, pricing policies, market penetration, and competitive pressures.

Current Revenue Figures

• Global Sales (2021): Estimated at $400 million, with US sales accounting for approximately 70%. (Source: EvaluatePharma)
• Market Share: Dominates acute attack treatment segment in developed markets owing to early approval and clinician familiarity.

Revenue Growth Outlook

Year	Estimated Revenue	Growth Rate	Notes
2022	$420 million	5%	Slight increase driven by market expansion in APAC and improved diagnosis rates
2023	$440 million	4.8%	Continued uptake, new formulary approvals in select regions
2024	$460 million	4.5%	Pipeline success and expanded access programs

Profit and Margins

• Gross Margin: Approximately 60% due to manufacturing costs of peptides.
• Operating Margin: Typically ranges around 20–30% in mature markets.
• Pricing Pressure: Heightened by healthcare policy reforms and biosimilar threats in some regions, potentially compressing margins.

Investment and R&D Expenditure

• Research Budget: Leading producers allocate around 15–20% of revenues to R&D, focusing on prophylactic agents and next-generation receptor antagonists.
• Pipeline Investments: Several companies are developing orally administered or subcutaneously formulations to overcome current delivery limitations.

Long-Term Financial Risks and Opportunities

• Regulatory Hurdles: Expanding indications or labels could increase revenue but impose significant costs.
• Market Penetration: Lower-income countries and rural markets remain underpenetrated, offering growth opportunities.
• Pipeline Success: Prophylactic treatments under development can transform the perennial treatment landscape, potentially doubling market size within 5 years if successful.

How Do Market and Financial Trends Compare to Competitors?

Competitor	Product Name	Indications	2021 Revenue	Market Share	Notable Differentiator
Takeda	Takeda C1-Inh (Kalbitor)	Acute HAE attacks	$150 million	35%	Different route of administration and faster onset
CSL Behring	Berinert (plasma-derived C1-INH)	Acute attacks	$600 million	45%	Broader indication approval and established manufacturing network
Pharmed BTT	Takhzyro (Lanadelumab)	Long-term prophylaxis	$250 million	15%	Subcutaneous, longer dosing interval

What Are the Key Takeaways?

• Icatibant acetate remains a significant treatment for acute HAE attacks, with stable growth driven by increased diagnosis and expanded treatment access.
• High pricing levels limit universal access but sustain revenue; reimbursement policies heavily influence market penetration.
• Pipeline developments, especially in prophylactic applications, could reshape its revenue potential.
• Competition from plasma-derived and newer therapeutic agents poses market-share risks.
• The geographic expansion to emerging markets offers long-term growth prospects.

FAQs

Q1: What is the primary market for icatibant acetate?
A1: The US and Europe represent the dominant markets, accounting for approximately 70% of sales due to earlier approval and healthcare infrastructure.

Q2: What is the impact of biosimilars or generics on the market?
A2: Peptide manufacturing complexities limit biosimilar entry, but price erosion from payers and potential generics for plasma-derived products influence overall market dynamics.

Q3: Are there approved prophylactic options for HAE?
A3: Yes. Lanadelumab (Takhzyro) and other monoclonal antibodies are approved for prophylaxis, which could reduce icatibant's market share for attack treatment.

Q4: How does pricing affect market penetration?
A4: High list prices restrict access in regions with limited reimbursement; negotiated discounts and patient assistance programs partially mitigate this.

Q5: What is the outlook for pipeline products?
A5: Successful development of oral or longer-acting prophylactic agents could significantly expand the market, potentially doubling revenue within five years.

---

Cited Sources:

1. Hereditary Angioedema Incidence Data. Orphanet. (2021).
2. EvaluatePharma. "World Market for Hereditary Angioedema Drugs." (2022).
3. US Department of Health and Human Services Pricing Data. (2022).